Skip to main content
Erschienen in: World Journal of Urology 6/2020

03.09.2019 | Original Article

Biopsy Grade Group as a reliable prognostic factor for BCR in Afro-Caribbean men with intermediate- and high-risk prostate cancer

verfasst von: Emmanuel Perrot, Sofiane Seddik, Gilles Gourtaud, Rémi Eyraud, Virginie Roux, Clément Moureaux, Pascal Blanchet, Laurent Brureau

Erschienen in: World Journal of Urology | Ausgabe 6/2020

Einloggen, um Zugang zu erhalten

Abstract

Purpose

The Grade Group (GG) classification is recommended by guidelines as a reliable prognostic factor of prostate cancer. However, most studies have been performed on the Caucasian population. Our objective was to validate GG classification as a safe way to classify intermediate- and high-risk patients with African ancestry.

Patients and methods

This was a retrospective study in an Afro-Caribbean population. A total of 1236 patients were included between 2000 and 2015. Patients were stratified according to (GG). Survival analysis was performed using the Kaplan–Meier method, univariate and multivariate analyses using the Cox model.

Results

There was no significant difference at 5 and 10-year BCR-free survival between the intermediate- and high-risk groups, based on the D’Amico classification. There was a highly significant difference in BCR-free survival at 5 (p < 0.0001) and 10 years (p < 0.0001) for patients of GG 1 and 2 vs 3, 4, and 5, respectively. There was no significant difference in 5-year BCR-free survival of patients of GG grades 1 and 2, whether lymph-node dissection was performed or not. There was a significant difference between GG 2 and 3 patients in 5 (p = 0.008) and 10-year BCR-free survival (p = 0.01). High PSA (p < 0.0001), pathological GG ≥ 3 (p < 0.0001), pathological stage pT3 (p < 0.0001) and positive margins (p < 0.0001) were factors for BCR in multivariate analysis.

Conclusion

The GG 2015 classification appears to be a better prognostic factor than D’Amico classification for intermediate- and high-risk Afro-Caribbean patients.
Literatur
1.
Zurück zum Zitat Center MM, Jemal A, Lortet-Tieulent J, Ward E, Ferlay J, Brawley O et al (2012) International variation in prostate cancer incidence and mortality rates. Eur Urol 61(6):1079–1092CrossRef Center MM, Jemal A, Lortet-Tieulent J, Ward E, Ferlay J, Brawley O et al (2012) International variation in prostate cancer incidence and mortality rates. Eur Urol 61(6):1079–1092CrossRef
2.
Zurück zum Zitat D’Amico AV, Whittington R, Malkowicz SB, Schultz D, Blank K, Broderick GA (1998) Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 280(11):969–974CrossRef D’Amico AV, Whittington R, Malkowicz SB, Schultz D, Blank K, Broderick GA (1998) Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 280(11):969–974CrossRef
3.
Zurück zum Zitat Eifler JB, Feng Z, Lin BM, Partin MT, Humphreys EB, Han M et al (2013) An updated prostate cancer staging nomogram (Partin tables) based on cases from 2006 to 2011. BJU Int 111(1):22–29CrossRef Eifler JB, Feng Z, Lin BM, Partin MT, Humphreys EB, Han M et al (2013) An updated prostate cancer staging nomogram (Partin tables) based on cases from 2006 to 2011. BJU Int 111(1):22–29CrossRef
4.
Zurück zum Zitat Briganti A, Larcher A, Abdollah F, Capitanio U, Gallina A, Suardi N et al (2012) Updated nomogram predicting lymph node invasion in patients with prostate cancer undergoing extended pelvic lymph node dissection: the essential importance of percentage of positive cores. Eur Urol 61(3):480–487CrossRef Briganti A, Larcher A, Abdollah F, Capitanio U, Gallina A, Suardi N et al (2012) Updated nomogram predicting lymph node invasion in patients with prostate cancer undergoing extended pelvic lymph node dissection: the essential importance of percentage of positive cores. Eur Urol 61(3):480–487CrossRef
5.
Zurück zum Zitat Pierorazio PM, Walsh PW, Partin AW, Epstein JI (2013) Prognostic Gleason grade grouping: data based on the modified Gleason scoring system. BJU Int 111:753–760CrossRef Pierorazio PM, Walsh PW, Partin AW, Epstein JI (2013) Prognostic Gleason grade grouping: data based on the modified Gleason scoring system. BJU Int 111:753–760CrossRef
6.
Zurück zum Zitat Samaratunga H, Delahunt B, Gianduzzo T, Coughlin G, Duffy D, LeFevre I et al (2015) The prognostic significance of the 2014 International Society of Urological Pathology (ISUP) grading system for prostate cancer. Pathology 47(6):515–519CrossRef Samaratunga H, Delahunt B, Gianduzzo T, Coughlin G, Duffy D, LeFevre I et al (2015) The prognostic significance of the 2014 International Society of Urological Pathology (ISUP) grading system for prostate cancer. Pathology 47(6):515–519CrossRef
7.
Zurück zum Zitat Epstein JI, Zelefsky MJ, Sjoberg DD, Nelson JB, Egevad L, Magi-Galluzzi C et al (2016) A contemporary prostate cancer grading system: a validated alternative to the gleason score. Eur Urol 69(3):428–435CrossRef Epstein JI, Zelefsky MJ, Sjoberg DD, Nelson JB, Egevad L, Magi-Galluzzi C et al (2016) A contemporary prostate cancer grading system: a validated alternative to the gleason score. Eur Urol 69(3):428–435CrossRef
8.
Zurück zum Zitat Leyh-Bannurah SR, Gazdovich S, Budäus L, Zaffuto E, Dell’Oglio P, Briganti A et al (2017) Population-based external validation of the updated 2012 partin tables in contemporary North American prostate cancer patients. Prostate 77(1):105–113CrossRef Leyh-Bannurah SR, Gazdovich S, Budäus L, Zaffuto E, Dell’Oglio P, Briganti A et al (2017) Population-based external validation of the updated 2012 partin tables in contemporary North American prostate cancer patients. Prostate 77(1):105–113CrossRef
9.
Zurück zum Zitat Brureau L, Emeville E, Multigner L, Blanchet P (2018) Predictors of biochemical recurrence after radical prostatectomy in an Afro-Caribbean population in Guadeloupe (French West Indies). Prog Urol 28(8–9):442–449CrossRef Brureau L, Emeville E, Multigner L, Blanchet P (2018) Predictors of biochemical recurrence after radical prostatectomy in an Afro-Caribbean population in Guadeloupe (French West Indies). Prog Urol 28(8–9):442–449CrossRef
10.
Zurück zum Zitat Catalona WJ, Smith DS, Ratliff TL, Dodds KM, Coplen DE, Yuan JJ et al (1991) Measurement of prostate-specific antigen in serum as a screening test for prostate cancer. N Engl J Med 324:1156–1161CrossRef Catalona WJ, Smith DS, Ratliff TL, Dodds KM, Coplen DE, Yuan JJ et al (1991) Measurement of prostate-specific antigen in serum as a screening test for prostate cancer. N Engl J Med 324:1156–1161CrossRef
11.
Zurück zum Zitat Henderson RJ, Eastham JA, Culkin DJ, Kattan MW, Whatley T, Mata J et al (1997) Prostate-specific antigen (PSA) and PSA density: racial differences in men without prostate cancer. J Natl Cancer Inst 89(2):134–138CrossRef Henderson RJ, Eastham JA, Culkin DJ, Kattan MW, Whatley T, Mata J et al (1997) Prostate-specific antigen (PSA) and PSA density: racial differences in men without prostate cancer. J Natl Cancer Inst 89(2):134–138CrossRef
12.
Zurück zum Zitat Fowler JE Jr, Bigler SA (2002) Racial differences in prostate carcinogenesis. Histologic and clinical observations. Urol Clin N Am 29(1):183–191CrossRef Fowler JE Jr, Bigler SA (2002) Racial differences in prostate carcinogenesis. Histologic and clinical observations. Urol Clin N Am 29(1):183–191CrossRef
13.
Zurück zum Zitat Sarma AV, St Sauver JL, Jacobson DJ, McGree ME, Klee GG, Lieber MM et al (2014) Racial differences in longitudinal changes in serum prostate-specific antigen levels: the Olmsted County Study and the Flint Men’s Health Study. Urology 83(1):88–93CrossRef Sarma AV, St Sauver JL, Jacobson DJ, McGree ME, Klee GG, Lieber MM et al (2014) Racial differences in longitudinal changes in serum prostate-specific antigen levels: the Olmsted County Study and the Flint Men’s Health Study. Urology 83(1):88–93CrossRef
14.
Zurück zum Zitat Ellis SD, Blackard B, Carpenter WR, Mishel M, Chen RC, Godley PA et al (2013) Receipt of national comprehensive cancer network guideline-concordant prostate cancer care among African American and Caucasian American men in North Carolina. Cancer 119(12):2282–2290CrossRef Ellis SD, Blackard B, Carpenter WR, Mishel M, Chen RC, Godley PA et al (2013) Receipt of national comprehensive cancer network guideline-concordant prostate cancer care among African American and Caucasian American men in North Carolina. Cancer 119(12):2282–2290CrossRef
15.
Zurück zum Zitat Lucia MS, Bostwick DG, Somerville MC, Fowler IL, Rittmaster RS (2013) Comparison of Classic and International Society of Urological Pathology 2005 Modified Gleason grading using needle biopsies from the Reduction by Dutasteride of Prostate Cancer Events (REDUCE) trial. Arch Pathol Lab Med 137(12):1740–1746CrossRef Lucia MS, Bostwick DG, Somerville MC, Fowler IL, Rittmaster RS (2013) Comparison of Classic and International Society of Urological Pathology 2005 Modified Gleason grading using needle biopsies from the Reduction by Dutasteride of Prostate Cancer Events (REDUCE) trial. Arch Pathol Lab Med 137(12):1740–1746CrossRef
16.
Zurück zum Zitat Grogan J, Gupta R, Mahon KL, Stricker PD, Haynes AM, Delprado W et al (2017) Predictive value of the 2014 International Society of Urological Pathology grading system for prostate cancer in patients undergoing radical prostatectomy with long-term follow-up. BJU Int 120(5):651–658CrossRef Grogan J, Gupta R, Mahon KL, Stricker PD, Haynes AM, Delprado W et al (2017) Predictive value of the 2014 International Society of Urological Pathology grading system for prostate cancer in patients undergoing radical prostatectomy with long-term follow-up. BJU Int 120(5):651–658CrossRef
17.
Zurück zum Zitat Lavery HJ, Droller MJ (2012) Do Gleason patterns 3 and 4 prostate cancer represent separate disease states? J Urol 188(5):1667–1675CrossRef Lavery HJ, Droller MJ (2012) Do Gleason patterns 3 and 4 prostate cancer represent separate disease states? J Urol 188(5):1667–1675CrossRef
18.
Zurück zum Zitat Huang CC, Kong MX, Zhou M, Rosenkrantz AB, Taneja SS, Melamed J et al (2014) Gleason score 3 + 4 = 7 prostate cancer with minimal quantity of gleason pattern 4 on needle biopsy is associated with low-risk tumor in radical prostatectomy specimen. Am J Surg Pathol 38(8):1096–1101CrossRef Huang CC, Kong MX, Zhou M, Rosenkrantz AB, Taneja SS, Melamed J et al (2014) Gleason score 3 + 4 = 7 prostate cancer with minimal quantity of gleason pattern 4 on needle biopsy is associated with low-risk tumor in radical prostatectomy specimen. Am J Surg Pathol 38(8):1096–1101CrossRef
19.
Zurück zum Zitat Schulman AA, Howard LE, Tay KJ, Tsivian E, Sze C, Amling CL et al (2017) Validation of the 2015 prostate cancer grade groups for predicting long-term oncologic outcomes in a shared equal-access health system. Cancer 123(21):4122–4129CrossRef Schulman AA, Howard LE, Tay KJ, Tsivian E, Sze C, Amling CL et al (2017) Validation of the 2015 prostate cancer grade groups for predicting long-term oncologic outcomes in a shared equal-access health system. Cancer 123(21):4122–4129CrossRef
20.
Zurück zum Zitat Bandini M, Marchioni M, Preisser F, Nazzani S, Tian Z, Fossati N (2019) A head-to-head comparison of four prognostic models for prediction of lymph node invasion in African American and caucasian individuals. Eur Urol Focus 5(3):449–456CrossRef Bandini M, Marchioni M, Preisser F, Nazzani S, Tian Z, Fossati N (2019) A head-to-head comparison of four prognostic models for prediction of lymph node invasion in African American and caucasian individuals. Eur Urol Focus 5(3):449–456CrossRef
Metadaten
Titel
Biopsy Grade Group as a reliable prognostic factor for BCR in Afro-Caribbean men with intermediate- and high-risk prostate cancer
verfasst von
Emmanuel Perrot
Sofiane Seddik
Gilles Gourtaud
Rémi Eyraud
Virginie Roux
Clément Moureaux
Pascal Blanchet
Laurent Brureau
Publikationsdatum
03.09.2019
Verlag
Springer Berlin Heidelberg
Erschienen in
World Journal of Urology / Ausgabe 6/2020
Print ISSN: 0724-4983
Elektronische ISSN: 1433-8726
DOI
https://doi.org/10.1007/s00345-019-02931-3

Weitere Artikel der Ausgabe 6/2020

World Journal of Urology 6/2020 Zur Ausgabe

Update Urologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.